Deng Alan Y
Research Centre, Centre hospitalier de l'Université de Montréal, Montréal, QC H2X 0A9, Canada.
Rev Cardiovasc Med. 2022 Apr 1;23(4):119. doi: 10.31083/j.rcm2304119. eCollection 2022 Apr.
Possessing blood pressure in normal ranges is considered healthy, and does not warrant medical attention for obvious clinical reasons. However, to realize normotension and then maintain it even when confronted with a hypertensive threat must have its biological 'shield of armour'. While sensitivity to hypertension has been widely recognized and studied, inherent mechanisms that enable a physiological resistance to hypertension to occur have received little attention. Recent advances in normotension genetics have produced unexpected insights. A hypertension 'suppressor' likely inhabits the normotensive genome of inbred Lewis rats. This suppressor behaves as a 'master' control capable of functionally abrogating the effects of hypertension-promoting alleles from multiple quantitative trait loci. This conceptual advancement lays the foundation for uncovering an anti-hypertension gene. Discovering its identity will assist our attempts at developing innovative diagnostic and therapeutic strategies for circumventing and treating hypertension. This new domain of suppressing hypertension goes beyond the conventional pharmacological treatments of hypertension before symptoms appear. For this purpose, a valid theoretical basis and framework is needed that can interpret the experimental data and produce testable predictions for authenticating, enriching or amending the normotension paradigm in the future.
血压处于正常范围被认为是健康的，并且由于明显的临床原因无需就医。然而，要实现血压正常并在面临高血压威胁时维持这一状态，必然有其生物学上的“防护甲”。虽然对高血压的敏感性已得到广泛认可和研究，但使生理上对高血压产生抵抗的内在机制却很少受到关注。正常血压遗传学的最新进展带来了意想不到的见解。一种高血压“抑制因子”可能存在于近交系刘易斯大鼠的正常血压基因组中。这种抑制因子表现为一种“主控”因子，能够在功能上消除来自多个数量性状位点的促高血压等位基因的影响。这一概念上的进展为发现抗高血压基因奠定了基础。确定其身份将有助于我们开发创新的诊断和治疗策略，以规避和治疗高血压。这个抑制高血压的新领域超越了症状出现前高血压的传统药物治疗。为此，需要一个有效的理论基础和框架，来解释实验数据，并产生可测试的预测，以便在未来验证、丰富或修正正常血压范式。
